Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Cefazolin in Pediatric Surgery
NCT03231228Phase 4Terminated
- Sponsor
- B. Braun
- Start
- Nov 2017
- Primary completion
- Jul 2019
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, open-label trial of cefazolin in post-operative infection (2 arms), sponsored by B. Braun. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at 8 days. Started Nov 2017; status: terminated.
02
Drugs
cefazolin
03
Conditions
post-operative infection
Beyond the preview
Go deeper on NCT03231228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03231228.